REG - IXICO plc - Change of Auditor

IXICOAnnouncement

15/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231215:nRSO9003Wa&default-theme=true

RNS Number : 9003W  IXICO plc  15 December 2023

15 December 2023

IXICO plc

("IXICO" or "Group" or "Company")

 

Change of Auditor

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, announces that the Board has approved the
appointment of Moore Kingston Smith LLP ("MKS") as the Company's new provider
of external audit related services and that Grant Thornton UK LLP ("Grant
Thornton") has resigned as the Company's auditor with immediate effect.

 

As detailed further in the Annual Report and Accounts 2023, this appointment
follows a competitive tender process, running from May 2023 and concluding in
October 2023, for the Group's FY24 audit services. A resolution to appoint MKS
as auditors of the Company will be put forward at the 2024 Annual General
Meeting, which will take place at 10:30am on 25 January 2024.

 

Grant Thornton has been involved in auditing the Group since 2013 and we thank
them for their services over this time. Grant Thornton has confirmed to the
Company that there are no matters connected with their ceasing to hold office
that need to be brought to the attention of the members or creditors of the
Company for the purposes of section 519 of the Companies Act 2006.

 

 

 

For further information please contact:

 

 IXICO plc                                                                          +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Securities PLC (Nominated adviser and sole broker)                       +44 (0) 20 7397 8900
 Giles Balleny (Corporate Finance)

 Charlie Combe (ECM)
 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPBRBDDCXBDGXS